Journal of Jilin University(Medicine Edition) ›› 2022, Vol. 48 ›› Issue (1): 163-171.doi: 10.13481/j.1671-587X.20220120
• Research in clinical medicine • Previous Articles Next Articles
Lili QIN1,Xiaobo MA2,Tianye ZHAO1,Xuerong TAO1,Min ZHENG1,Xueying WANG1,Jiaxin YI1,Yanhua WU1(),Jing JIANG1()
Received:
2021-05-21
Online:
2022-01-28
Published:
2022-01-17
Contact:
Yanhua WU,Jing JIANG
E-mail:wuyanhua@jlu.edu.cn;jiangjing19702000@jlu.edu.cn
CLC Number:
Lili QIN,Xiaobo MA,Tianye ZHAO,Xuerong TAO,Min ZHENG,Xueying WANG,Jiaxin YI,Yanhua WU,Jing JIANG. Effects of MMP-9 and TIMP-1 expressions on prognostic evaluation of gastric cancer patients after radical gastrectomy[J].Journal of Jilin University(Medicine Edition), 2022, 48(1): 163-171.
"
Tab. 1 Baseline characteristics ofgastric cancer patients | |||
---|---|---|---|
Characteristic | Number (n) | Proportion (η/%) | |
Age(year) | |||
≤65 | 162 | 60.0 | |
>65 | 108 | 40.0 | |
Gender | |||
Female | 65 | 24.1 | |
Male | 205 | 75.9 | |
Tumor size | |||
<5 cm | 82 | 30.4 | |
≥5 cm | 188 | 69.6 | |
Type | |||
Signet ring cell | 30 | 11.1 | |
Others | 240 | 88.9 | |
Histological grade | |||
Low grade | 57 | 21.1 | |
High grade | 213 | 78.9 | |
Chemotherapy | |||
Yes | 118 | 43.7 | |
No | 152 | 56.3 | |
TNM stage | |||
Ⅰ/Ⅱ stage | 165 | 61.1 | |
Ⅲ stage | 105 | 38.9 | |
Event | |||
Live | 99 | 36.7 | |
Lose | 11 | 4.1 | |
Death | 160 | 59.2 | |
MMP-9 | |||
- | 188 | 69.6 | |
+ | 82 | 30.4 | |
TIMP-1 | |||
- | 199 | 73.7 | |
+ | 71 | 26.3 | |
MMP-9/TIMP-1 | |||
-/+ | 47 | 17.4 | |
-/- | 141 | 52.2 | |
+/- | 58 | 21.5 | |
+/+ | 24 | 8.9 |
Tab.2
Distributions of MMP-9 and TIMP-1 expressions in cancer tissue of gastric cancer patients with different clinicopathological parameters"
Clinicopathological parameters | MMP-9-/TIMP-1- (n=141) | MMP-9+/TIMP-1-(n=58) | MMP-9-/TIMP-1+ (n=47) | MMP-9+/TIMP-1+ (n=24) | P | |
---|---|---|---|---|---|---|
Age(year) | ||||||
≤65 | 86(61.0) | 29(50.0) | 31(66.0) | 16(66.7) | 0.306 | |
>65 | 55(39.0) | 29(50.0) | 16(34.0) | 8(33.3) | ||
Gender | ||||||
Female | 28(19.9) | 14(24.1) | 17(36.2) | 6(25.0) | 0.161 | |
Male | 113(80.1) | 44(75.9) | 30(63.8) | 18(75.0) | ||
Tumor size | ||||||
<5 cm | 45(31.9) | 13(22.4) | 19(40.4) | 5(20.8) | 0.159 | |
≥5 cm | 96(68.1) | 45(77.6) | 28(59.6) | 19(79.2) | ||
Type | ||||||
Others | 127(90.1) | 51(87.9) | 42(89.4) | 20(83.3) | 0.740* | |
Signet ring cell | 14(9.9) | 7(12.1) | 5(10.6) | 4(16.7) | ||
Grade | ||||||
Low | 30(21.3) | 9(15.5) | 12(25.5) | 6(25.0) | 0.602 | |
High | 111(78.7) | 49(84.5) | 35(74.5) | 18(75.0) | ||
Chemotherapy | ||||||
Yes | 63(44.7) | 18(31.0) | 23(48.9) | 14(58.3) | 0.092 | |
No | 78(55.3) | 40(69.0) | 24(51.1) | 10(41.7) | ||
TNM stage | ||||||
Ⅰ/Ⅱ | 85(60.3) | 37(63.8) | 27(57.4) | 16(66.7) | 0.851 | |
Ⅲ | 56(39.7) | 21(36.2) | 20(42.6) | 8(33.3) |
Tab.3
Univariate Cox regression analysis on prognosis of gastric cancer patients"
Clinicopathological parameter | n | Number of event [n(η/%)] | MST* (month) | Ρ |
---|---|---|---|---|
Age(year) | ||||
≤65 | 162 | 90(55.6) | 36.0 | 0.241 |
>65 | 108 | 70(64.8) | 27.0 | |
Gender | ||||
Female | 65 | 40(61.5) | 26.0 | 0.549 |
Male | 205 | 120(58.5) | 33.0 | |
Tumor size | ||||
<5 cm | 82 | 44(53.7) | 42.0 | 0.114 |
≥5 cm | 188 | 116(61.7) | 26.0 | |
Grade | ||||
Low | 57 | 26(45.6) | 72.0 | 0.007 |
High | 213 | 134(62.9) | 26.0 | |
Type | ||||
Others | 30 | 20(66.7) | 28.0 | 0.318 |
Signet ring | 240 | 140(58.3) | 31.0 | |
Chemotherapy | ||||
Yes | 118 | 57(48.3) | 47.0 | <0.001 |
No | 152 | 103(67.8) | 21.0 | |
TNM stage | ||||
Ⅰ/Ⅱ | 165 | 77(46.7) | 72.0 | <0.001 |
Ⅲ | 105 | 83(79.0) | 15.0 |
Tab.4
Multivariate Cox regression analysis on prognosis of gastric cancer patients"
Clinicopathological parameter | B | SE | Wald | HR | 95%CI | Ρ |
---|---|---|---|---|---|---|
Age | 0.063 | 0.169 | 0.137 | 1.065 | 0.764-1.483 | 0.711 |
Gender | 0.013 | 0.187 | 0.005 | 1.013 | 0.702-1.461 | 0.944 |
Tumor size | 0.170 | 0.184 | 0.847 | 1.185 | 0.826-1.701 | 0.357 |
Tumor type | -0.071 | 0.245 | 0.083 | 0.932 | 0.576-1.507 | 0.773 |
Histological grade | 0.413 | 0.229 | 3.247 | 1.511 | 0.964-2.366 | 0.072 |
Chemotherapy | 0.628 | 0.173 | 13.118 | 1.873 | 1.334-2.631 | <0.001 |
TNM stage | 0.833 | 0.168 | 24.680 | 2.301 | 1.656-3.197 | <0.001 |
MMP-9/TIMP-1 | ||||||
MMP-9-/TIMP-1+ | - | - | 7.093 | - | - | 0.029 |
MMP-9-/TIMP-1- | -0.379 | 0.203 | 3.489 | 0.684 | 0.460-1.019 | 0.062 |
MMP-9+/TIMP-1+/- | -0.623 | 0.235 | 7.003 | 0.537 | 0.338-0.851 | 0.008 |
“-”:No data. |
1 | BOURBOULIA D, STETLER-STEVENSON W G. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion[J]. Semin Cancer Biol, 2010, 20(3): 161-168. |
2 | TAKEHA S, FUJIYAMA Y, BAMBA T, et al. Stromal expression of MMP-9 and urokinase receptor is inversely associated with liver metastasis and with infiltrating growth in human colorectal cancer: a novel approach from immune/inflammatory aspect[J]. Jpn J Cancer Res, 1997, 88(1): 72-81. |
3 | JOBIN P G, BUTLER G S, OVERALL C M. New intracellular activities of matrix metalloproteinases shine in the moonlight[J]. Biochim Biophys Acta Mol Cell Res, 2017, 1864(11 Pt A): 2043-2055. |
4 | EGEBLAD M, WERB Z. New functions for the matrix metalloproteinases in cancer progression[J]. Nat Rev Cancer, 2002, 2(3): 161-174. |
5 | HUANG H. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: recent advances[J]. Sensors (Basel), 2018, 18(10):E3249. |
6 | VILEN S T, SALO T, SORSA T, et al. Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma[J]. Sci World J, 2013, 2013: 920595. |
7 | ROY R, YANG J, MOSES M A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer[J]. J Clin Oncol, 2009, 27(31): 5287-5297. |
8 | SONG G, XU S, ZHANG H, et al. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway[J]. J Exp Clin Cancer Res, 2016, 35(1): 148. |
9 | SEO Y S, PARK J J, KIM J H, et al. Usefulness of MMP-9/TIMP-1 in predicting tumor recurrence in patients undergoing curative surgical resection for gastric carcinoma[J]. Dig Dis Sci, 2007, 52(3): 753-759. |
10 | ZHANG Y, QIN L, MA X, et al. Coexpression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 as a prognostic biomarker in gastric cancer[J]. Dis Markers, 2020, 2020: 8831466. |
11 | ZHANG S, LI L, LIN J Y, et al. Imbalance between expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in invasiveness and metastasis of human gastric carcinoma[J]. World J Gastroenterol, 2003, 9(5): 899-904. |
12 | LIAN P L, LIU Z, YANG G Y, et al. Integrin αvβ6 and matrix metalloproteinase 9 correlate with survival in gastric cancer[J].World J Gastroenterol,2016,22(14): 3852-3859. |
13 | PUJADA A, WALTER L, PATEL A, et al. Matrix metalloproteinase MMP9 maintains epithelial barrier function and preserves mucosal lining in colitis associated cancer[J]. Oncotarget, 2017, 8(55): 94650-94665. |
14 | SCORILAS A, KARAMERIS A, ARNOGIANNAKI N,et al. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients[J]. Br J Cancer, 2001, 84(11): 1488-1496. |
15 | KOSKENSALO S, HAGSTRÖM J, LINDER N,et al. Lack of MMP-9 expression is a marker for poor prognosis in Dukes' B colorectal cancer[J]. BMC Clin Pathol, 2012, 12: 24. |
16 | SAITO K, TAKEHA S, SHIBA K, et al. Clinicopathologic significance of urokinase receptor- and MMP-9-positive stromal cells in human colorectal cancer: functional multiplicity of matrix degradation on hematogenous metastasis[J]. Int J Cancer, 2000, 86(1): 24-29. |
17 | BISWAS M H, DU C, ZHANG C, et al. Protein kinase D1 inhibits cell proliferation through matrix metalloproteinase-2 and matrix metalloproteinase-9 secretion in prostate cancer[J].Cancer Res,2010,70(5): 2095-2104. |
18 | ZHANG Z Y, AMOROSA L F, COYLE S M, et al. Proteolytic cleavage of AMPKα and intracellular MMP9 expression are both required for TLR4-mediated mTORC1 activation and HIF-1α expression in leukocytes[J]. J Immunol, 2015, 195(5): 2452-2460. |
19 | LÓPEZ-OTÍN C, MATRISIAN L M. Emerging roles of proteases in tumour suppression[J]. Nat Rev Cancer, 2007, 7(10): 800-808. |
20 | WALTER L, PUJADA A, BHATNAGAR N, et al. Epithelial derived-matrix metalloproteinase (MMP9) exhibits a novel defensive role of tumor suppressor in colitis associated cancer by activating MMP9-Notch1-ARF-p53 axis[J]. Oncotarget, 2017, 8(1): 364-378. |
21 | GARG P, JEPPSSON S, DALMASSO G, et al. Notch1 regulates the effects of matrix metalloproteinase-9 on colitis-associated cancer in mice[J]. Gastroenterology, 2011, 141(4): 1381-1392. |
22 | LI L, ZHANG S, LIN H, et al. Relationship of expression unbalance of matrix metalloproteinase and tissue inhibitor of metalloproteinase to invasiveness and metastasis in gastric carcinomas[J].Ai Zheng,2002,21(3): 305-310. |
23 | GRÜNWALD B, SCHOEPS B, KRÜGER A. Recognizing the molecular multifunctionality and interactome of TIMP-1[J]. Trends Cell Biol, 2019, 29(1): 6-19. |
24 | YOSHIKAWA T, TSUBURAYA A, KOBAYASHI O,et al. Prognostic value of tissue inhibitor of matrix metalloproteinase-1 in plasma of patients with gastric cancer[J]. Cancer Lett, 2000, 151(1): 81-86. |
25 | SATO H, KIDA Y, MAI M, et al. Expression of genes encoding type Ⅳ collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells[J]. Oncogene, 1992, 7(1): 77-83. |
26 | HAMANO Y, ZEISBERG M, SUGIMOTO H, et al. Physiological levels of tumstatin, a fragment of collagen Ⅳ alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin[J]. Cancer Cell, 2003, 3(6): 589-601. |
27 | HELJASVAARA R, NYBERG P, LUOSTARINEN J,et al. Generation of biologically active endostatin fragments from human collagen XⅧ by distinct matrix metalloproteases[J]. Exp Cell Res, 2005, 307(2): 292-304. |
28 | JACKSON H W, DEFAMIE V, WATERHOUSE P, et al. TIMPs: versatile extracellular regulators in cancer[J]. Nat Rev Cancer, 2017, 17(1): 38-53. |
29 | OVERALL C M, KLEIFELD O. Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy[J]. Nat Rev Cancer, 2006, 6(3): 227-239. |
30 | UNSAL KILIC D, UNER A, AKYUREK N, et al. Matrix metalloproteinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy[J]. Int J Radiat Oncol Biol Phys, 2007, 67(1): 196-203. |
[1] | Liantao HU,Wenjun DENG,Shizhen LU,Luo SUN,Xuebing LI,Chuhao LI,Xinran WANG,chunbing ZHANG,Yue LI,Weiqun WANG. Bioinformatics analysis on CC chemokine ligand 20 expression in hepatocellular carcinoma tissue and its effect on prognostic assessment of liver hepatocellular carcinoma [J]. Journal of Jilin University(Medicine Edition), 2022, 48(4): 1010-1017. |
[2] | Shan GAO,Yutong WANG,Minqiu LU,Lei SHI,Bin CHU,Yuehua DING,Mengzhen WANG,Li BAO. Analysis on causes for early death and its risk factors of patients with multiple myeloma in era of novel drugs [J]. Journal of Jilin University(Medicine Edition), 2022, 48(3): 783-789. |
[3] | Chengsheng LI,Qihan BAO,Xiaoyan HAO,Qingzhong PAN,Suzhen WANG,Fuyan SHI. Establishment of prediction model for postoperative pancreatic cancer based on random forest algorithm [J]. Journal of Jilin University(Medicine Edition), 2022, 48(2): 426-435. |
[4] | Guangsong XU,Haibing JIANG,Jing PAN,Guoqing LI. Inhibitory effects of betulinic acid on migration and invasion of gastric cancer MGC-803 cells and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2022, 48(1): 122-128. |
[5] | Ying ZHAO,Danyu ZHAO,Chao LIU. Bioinformatics analysis on prognostic evaluation value of TXNDC11 gene in pan-cancer and its immunity regulation [J]. Journal of Jilin University(Medicine Edition), 2022, 48(1): 142-153. |
[6] | Shuzhen LI,Yajie CAO,Haiying GENG,Zengxiaorui CAI,Chunmei DAI,Youfeng WEN,Ning LI. Bioinformatics analysis based on expression level of HMMR in lung adenocarcinoma tissue and its impact on prognosis of LUAD patients [J]. Journal of Jilin University(Medicine Edition), 2021, 47(6): 1502-1509. |
[7] | Runhong MU,Yijiu AI,Yupeng LI,Rui LIN,Siping YE,Fang MA,Xiao GUO. Expression of recombinant human IL-17A in gastric cancer tissue and its effects on proliferation, invasion, migration and apoptosis of gastric cancer BGC-823 cells [J]. Journal of Jilin University(Medicine Edition), 2021, 47(6): 1510-1517. |
[8] | Yang YU,Sainan LIU,Yunkai LIU,Yong LI,Yichun QIAO,Yi CHENG. Bioinformatic analysis on expression characteristics of PRPS2 and its relationship with prognosis of breast cancer [J]. Journal of Jilin University(Medicine Edition), 2021, 47(5): 1229-1236. |
[9] | Aiping WEN,Le LUO,Zhiwei MENG,Jingji JIN,Honggui ZHOU,Jihong ZHU. Expression of Tip60 protein in endometrial adenocarcinoma tissue and its clinical significance [J]. Journal of Jilin University(Medicine Edition), 2021, 47(5): 1244-1249. |
[10] | Dan SU, Yi LIU, Manman CUI, Nian YANG, Yu HUANG, Wenjing HE. Evaluation of clinical effect of screening chemotherapy regimens in treatment of ovarian cancer based on miniPDX animal models [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 731-739. |
[11] | Dongkui ZHOU, Mingqian LU, Yaxin LIN, Xuesong FENG, Yan GAO, Hao SONG. Small cell carcinoma of gallbladder with liver and retroperitoneal lymph node metastasis: A case report and literature review [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 747-752. |
[12] | GUO Fei, ZHU Lin, XU Hong, XIE Zongyu, ZHANG Li, DENG Xuefei. Analysis on correlation between image features of chest MSCT and prognosis in patients with novel coronavirus pneumonia [J]. Journal of Jilin University(Medicine Edition), 2020, 46(04): 867-874. |
[13] | SHI Guanghuan, ZHOU Shiping, XU Dongsheng, WANG Xiu. Killing effect of amplified NK cells on gastric cancer cells and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2020, 46(03): 530-535. |
[14] | SONG Hongyun, PAN Ying, AN Furun, ZHANG Jiakui, YANG Dongdong, ZHAI Zhimin. Clinical characteristics of acute leukemia patients with complex karyotypes and their effects on prognosis [J]. Journal of Jilin University(Medicine Edition), 2020, 46(02): 377-382. |
[15] | XU Jianguo, CAO Hongtao, ZHANG Zilong, JI Baoyan, WANG Chunqiu, LI Shengdong, LIU Guoqing. Effects of LincRNA-p21 knockdown on growth and metastasis of gastric cancer cells and their mechanisms [J]. Journal of Jilin University(Medicine Edition), 2020, 46(02): 266-273. |